Cargando…
Differential levels of L-homocysteic acid and lysophosphatidylcholine (16:0) in sera of patients with ovarian cancer
Ovarian cancer (OVC) is one of the most difficult types of cancer to detect in the early stages of its development. There have been numerous attempts to identify a biomarker for OVC; however, an accurate diagnostic marker has yet to be identified. The present study profiled OVC candidate metabolites...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081284/ https://www.ncbi.nlm.nih.gov/pubmed/25013471 http://dx.doi.org/10.3892/ol.2014.2214 |
_version_ | 1782324087460200448 |
---|---|
author | KIM, SEUNG CHEOL KIM, MIN KYUNG KIM, YUN HWAN AHN, SUN-A KIM, KYUNG-HEE KIM, KUN KIM, WON KI LEE, JUN HWA CHO, JAE YOUL YOO, BYONG CHUL |
author_facet | KIM, SEUNG CHEOL KIM, MIN KYUNG KIM, YUN HWAN AHN, SUN-A KIM, KYUNG-HEE KIM, KUN KIM, WON KI LEE, JUN HWA CHO, JAE YOUL YOO, BYONG CHUL |
author_sort | KIM, SEUNG CHEOL |
collection | PubMed |
description | Ovarian cancer (OVC) is one of the most difficult types of cancer to detect in the early stages of its development. There have been numerous attempts to identify a biomarker for OVC; however, an accurate diagnostic marker has yet to be identified. The present study profiled OVC candidate metabolites from the serum to identify potential diagnostic markers for OVC. Data regarding low-mass ions (LMIs) in the serum were obtained using matrix-assisted laser desorption/ionization (MALDI)-time-of-flight analysis. MALDI-mass spectrometry (MS) analysis of each serum sample was repeated six times in order to reduce the likelihood of experimental errors. The intensity of the LMI mass peaks were normalized using total peak area sums. The normalized intensity of LMI was used in principal component analysis-discriminant analysis to differentiate between 142 patients with OVC and 100 healthy control participants. Liquid chromatography-MS/MS was used to identify the selected LMIs. Extracted ion chromatogram analysis was used to measure the relative quantity of candidate metabolites from the LMI mass peak areas. The concentration of common metabolites in the serum was determined using ELISA. The top 20 LMI mass peaks with a weigh factor over 0.05 were selected to distinguish between the patients with OVC and the controls. Among the LMIs, two with 184.05 and 496.30 m/z were identified as L-homocysteic acid (HCA) and lysophosphatidylcholine (LPC) (16:0), respectively. The relative quantity of LPC (16:0) was found to be decreased in the OVC serum (P=0.05), while the quantity of HCA was observed to be significantly higher in the OVC serum (P<0.001). HCA was not detected in 59 cases out of the 63 control participants; however, the majority of the cases of OVC (16/25) exhibited significantly higher quantities of HCA. When the cutoff was 10 nmol/ml, the sensitivity and specificity of HCA were 64.0 and 96.9%, respectively. The level of LPC (16:0) was significantly correlated with tumor grade (P=0.045). HCA and LPC (16:0) showed correlation with stage and tumor histology, but the limited sample size resulted in a lack of statistical significance. The findings of the present study suggest that HCA may have potential to be a biomarker for OVC. The stratified screening including LPC (16:0) did not significantly increase the power for OVC screening; however, the present study showed that profiling LMIs in serum may be useful for identifying candidate metabolites for OVC screening. |
format | Online Article Text |
id | pubmed-4081284 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-40812842014-07-10 Differential levels of L-homocysteic acid and lysophosphatidylcholine (16:0) in sera of patients with ovarian cancer KIM, SEUNG CHEOL KIM, MIN KYUNG KIM, YUN HWAN AHN, SUN-A KIM, KYUNG-HEE KIM, KUN KIM, WON KI LEE, JUN HWA CHO, JAE YOUL YOO, BYONG CHUL Oncol Lett Articles Ovarian cancer (OVC) is one of the most difficult types of cancer to detect in the early stages of its development. There have been numerous attempts to identify a biomarker for OVC; however, an accurate diagnostic marker has yet to be identified. The present study profiled OVC candidate metabolites from the serum to identify potential diagnostic markers for OVC. Data regarding low-mass ions (LMIs) in the serum were obtained using matrix-assisted laser desorption/ionization (MALDI)-time-of-flight analysis. MALDI-mass spectrometry (MS) analysis of each serum sample was repeated six times in order to reduce the likelihood of experimental errors. The intensity of the LMI mass peaks were normalized using total peak area sums. The normalized intensity of LMI was used in principal component analysis-discriminant analysis to differentiate between 142 patients with OVC and 100 healthy control participants. Liquid chromatography-MS/MS was used to identify the selected LMIs. Extracted ion chromatogram analysis was used to measure the relative quantity of candidate metabolites from the LMI mass peak areas. The concentration of common metabolites in the serum was determined using ELISA. The top 20 LMI mass peaks with a weigh factor over 0.05 were selected to distinguish between the patients with OVC and the controls. Among the LMIs, two with 184.05 and 496.30 m/z were identified as L-homocysteic acid (HCA) and lysophosphatidylcholine (LPC) (16:0), respectively. The relative quantity of LPC (16:0) was found to be decreased in the OVC serum (P=0.05), while the quantity of HCA was observed to be significantly higher in the OVC serum (P<0.001). HCA was not detected in 59 cases out of the 63 control participants; however, the majority of the cases of OVC (16/25) exhibited significantly higher quantities of HCA. When the cutoff was 10 nmol/ml, the sensitivity and specificity of HCA were 64.0 and 96.9%, respectively. The level of LPC (16:0) was significantly correlated with tumor grade (P=0.045). HCA and LPC (16:0) showed correlation with stage and tumor histology, but the limited sample size resulted in a lack of statistical significance. The findings of the present study suggest that HCA may have potential to be a biomarker for OVC. The stratified screening including LPC (16:0) did not significantly increase the power for OVC screening; however, the present study showed that profiling LMIs in serum may be useful for identifying candidate metabolites for OVC screening. D.A. Spandidos 2014-08 2014-06-03 /pmc/articles/PMC4081284/ /pubmed/25013471 http://dx.doi.org/10.3892/ol.2014.2214 Text en Copyright © 2014, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. |
spellingShingle | Articles KIM, SEUNG CHEOL KIM, MIN KYUNG KIM, YUN HWAN AHN, SUN-A KIM, KYUNG-HEE KIM, KUN KIM, WON KI LEE, JUN HWA CHO, JAE YOUL YOO, BYONG CHUL Differential levels of L-homocysteic acid and lysophosphatidylcholine (16:0) in sera of patients with ovarian cancer |
title | Differential levels of L-homocysteic acid and lysophosphatidylcholine (16:0) in sera of patients with ovarian cancer |
title_full | Differential levels of L-homocysteic acid and lysophosphatidylcholine (16:0) in sera of patients with ovarian cancer |
title_fullStr | Differential levels of L-homocysteic acid and lysophosphatidylcholine (16:0) in sera of patients with ovarian cancer |
title_full_unstemmed | Differential levels of L-homocysteic acid and lysophosphatidylcholine (16:0) in sera of patients with ovarian cancer |
title_short | Differential levels of L-homocysteic acid and lysophosphatidylcholine (16:0) in sera of patients with ovarian cancer |
title_sort | differential levels of l-homocysteic acid and lysophosphatidylcholine (16:0) in sera of patients with ovarian cancer |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081284/ https://www.ncbi.nlm.nih.gov/pubmed/25013471 http://dx.doi.org/10.3892/ol.2014.2214 |
work_keys_str_mv | AT kimseungcheol differentiallevelsoflhomocysteicacidandlysophosphatidylcholine160inseraofpatientswithovariancancer AT kimminkyung differentiallevelsoflhomocysteicacidandlysophosphatidylcholine160inseraofpatientswithovariancancer AT kimyunhwan differentiallevelsoflhomocysteicacidandlysophosphatidylcholine160inseraofpatientswithovariancancer AT ahnsuna differentiallevelsoflhomocysteicacidandlysophosphatidylcholine160inseraofpatientswithovariancancer AT kimkyunghee differentiallevelsoflhomocysteicacidandlysophosphatidylcholine160inseraofpatientswithovariancancer AT kimkun differentiallevelsoflhomocysteicacidandlysophosphatidylcholine160inseraofpatientswithovariancancer AT kimwonki differentiallevelsoflhomocysteicacidandlysophosphatidylcholine160inseraofpatientswithovariancancer AT leejunhwa differentiallevelsoflhomocysteicacidandlysophosphatidylcholine160inseraofpatientswithovariancancer AT chojaeyoul differentiallevelsoflhomocysteicacidandlysophosphatidylcholine160inseraofpatientswithovariancancer AT yoobyongchul differentiallevelsoflhomocysteicacidandlysophosphatidylcholine160inseraofpatientswithovariancancer |